cobas HBV
Roche Molecular Systems, Inc. · Decision date Aug 7, 2025
What did the FDA decide?
FDA records P150014/S057 as a supplement to PMA P150014, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 7, 2025.
FDA approval order statement
adding a new fill line
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Microbiology
- Decision date
- Aug 7, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P150014/S057
- Regulatory pathway
- PMA supplement
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- MKT
- Decision code
- OK30
- Decision date
- Aug 7, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Hepatitis Viral B DNA Detection.
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- MKT
- FDA device class
- 2
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P150014/S057 received
Application receipt date recorded by FDA.
P150014/S057 · FDA decision
30-Day Notice
P150014/S058 · Related supplement
cobas HBV
P150014/S056 · Related supplement
cobas HBV
Timeline entries are records held by MedtechLedger for P150014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas HBVP150014/S058 | Roche Molecular Systems, Inc. | PMA supplement | Sep 19, 2025 | FDA |
cobas HBVP150014/S056 | Roche Molecular Systems, Inc. | PMA supplement | Oct 17, 2025 | FDA |
Explore the linked device profile
Other records with product code MKT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Alinity m HBVP200013/S027 | Abbott Molecular, Inc. | PMA supplement | Oct 17, 2025 | FDA |
| Hologic, Inc. | PMA supplement | Oct 7, 2025 | FDA | |
Alinity m HBVP200013/S026 | Abbott Molecular, Inc. | PMA supplement | Sep 24, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Molecular Systems, Inc.
- Headquarters
- Not reported
- Brand website
- roche.com
- FDA applicant address
- 4300 Hacienda Dr., Pleasanton, CA, 94588
Sources and methodology
- Original FDA record: P150014/S057
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


